C4 Therapeutics Statistics
Share Statistics
C4 Therapeutics has 70.59M shares outstanding. The number of shares has increased by 40.96% in one year.
Shares Outstanding | 70.59M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.77% |
Owned by Institutions (%) | n/a |
Shares Floating | 56.92M |
Failed to Deliver (FTD) Shares | 1.71K |
FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 5.85M, so 8.29% of the outstanding shares have been sold short.
Short Interest | 5.85M |
Short % of Shares Out | 8.29% |
Short % of Float | 10.33% |
Short Ratio (days to cover) | 8.83 |
Valuation Ratios
The PE ratio is -2.12 and the forward PE ratio is -3.22.
PE Ratio | -2.12 |
Forward PE | -3.22 |
PS Ratio | 13.51 |
Forward PS | 12.7 |
PB Ratio | 1.14 |
P/FCF Ratio | -2.58 |
PEG Ratio | n/a |
Enterprise Valuation
C4 Therapeutics Inc. has an Enterprise Value (EV) of 224.85M.
EV / Earnings | -1.7 |
EV / Sales | 10.83 |
EV / EBITDA | -1.84 |
EV / EBIT | -1.62 |
EV / FCF | -2.07 |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.29.
Current Ratio | 6.34 |
Quick Ratio | 6.34 |
Debt / Equity | 0.29 |
Total Debt / Capitalization | 22.38 |
Cash Flow / Debt | -1.51 |
Interest Coverage | -101.26 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -44.27%.
Return on Equity (ROE) | -0.54% |
Return on Assets (ROA) | -0.35% |
Return on Capital (ROIC) | -44.27% |
Revenue Per Employee | 143.14K |
Profits Per Employee | -913.74K |
Employee Count | 145 |
Asset Turnover | 0.06 |
Inventory Turnover | 0 |
Taxes
Income Tax | 1.28M |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -11.52% in the last 52 weeks. The beta is 3.06, so C4 Therapeutics 's price volatility has been higher than the market average.
Beta | 3.06 |
52-Week Price Change | -11.52% |
50-Day Moving Average | 5.2 |
200-Day Moving Average | 6.17 |
Relative Strength Index (RSI) | 44.76 |
Average Volume (20 Days) | 1.10M |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $20.76M and earned -$132.49M in profits. Earnings per share was $-2.67.
Revenue | 20.76M |
Gross Profit | -96.95M |
Operating Income | -139.03M |
Net Income | -132.49M |
EBITDA | -122.10M |
EBIT | -139.03M |
Earnings Per Share (EPS) | -2.67 |
Balance Sheet
The company has $126.59M in cash and $70.98M in debt, giving a net cash position of $55.61M.
Cash & Cash Equivalents | 126.59M |
Total Debt | 70.98M |
Net Cash | 55.61M |
Retained Earnings | -528.38M |
Total Assets | 376.06M |
Working Capital | 229.94M |
Cash Flow
In the last 12 months, operating cash flow was -$106.84M and capital expenditures -$1.71M, giving a free cash flow of -$108.55M.
Operating Cash Flow | -106.84M |
Capital Expenditures | -1.71M |
Free Cash Flow | -108.55M |
FCF Per Share | -2.19 |
Margins
Gross margin is -467.09%, with operating and profit margins of -669.84% and -638.34%.
Gross Margin | -467.09% |
Operating Margin | -669.84% |
Pretax Margin | -632.17% |
Profit Margin | -638.34% |
EBITDA Margin | -588.28% |
EBIT Margin | -669.84% |
FCF Margin | -522.96% |
Dividends & Yields
CCCC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -60.96% |
FCF Yield | -35.07% |
Analyst Forecast
The average price target for CCCC is $8, which is 82.6% higher than the current price. The consensus rating is "Hold".
Price Target | $8 |
Price Target Difference | 82.6% |
Analyst Consensus | Hold |
Analyst Count | 6 |
Scores
Altman Z-Score | -0.84 |
Piotroski F-Score | 4 |